Atopic Dermatitis

These data, presented at the Winter Clinical conference, showed that roflumilast cream 0.15% led to positive results for patients with eczema.

These new, positive data from the ADORING Phase 3 development program showed no new safety signals with long-term use as well as a significant reduction in disease burden.

Advanced practice providers in dermatology discuss the key updates on the newly released guidelines on the management of AD and what this means for clinical practice.

Andrea Nguyen, PA reviews the mechanism of action of the biologics available for AD as well as the safety data on these systemic therapies.

The December 2023 month in review for dermatology covers major stories regarding a new FDA approval, several new treatment findings, and news on attitudes toward those with acne.

Expert advanced practice providers in dermatology talk about the different systemic and biologic therapies that are currently available and in development for AD.

Andrea Nguyen, PA, discusses some of the drawbacks she sees with topical corticosteroid treatment in AD in her practice.

These new data highlight the importance of larger trials to evaluate the persistence of this treatment’s efficacy and safety seen here.

Expert dermatologists share clinical pearls for providers treating patients with AD, and discuss the future of AD treatment.

Lisa Swanson, MD, PhD, highlights dermatology biologics coordinators as a resource for getting better access to JAK inhibitors.

Dermatology experts discuss the use of JAK inhibitors in clinical practice, highlighting their own experiences and use of JAKs alongside corticosteroids.

Andrea Nguyen, PA, shares which symptoms are most burdensome to patients with AD.

Expert advanced practice providers in dermatology discuss the diagnosis of atopic dermatitis.

These newly-updated parameters were a response by the ACAAI and the AAAAI to recent evidence that had become visible.

Expert dermatologists speak on shared-decision making between the patient and the provider when it comes to selecting the right therapy for AD.

Peter Lio, MD, reviews the contraindications of JAK inhibitors in AD and approaches for monitoring patients who are prescribed a JAK inhibitor.

Alexandra Golant, MD, comments on the boxed warnings on all currently approved JAK inhibitors, as well as the commonly used treatments in dermatology that have boxed warnings.

Expert dermatologists review the safety data of the current JAK inhibitors approved for AD, highlighting adverse events and long-term safety data.

This new data align with the acknowledged necessity for a disruption of the itch–scratch cycle in moderate-to-severe AD treatment among patients.

In this interview with Dr. Eichenfield, comparisons between ruxolitinib and other treatments for eczema were discussed.

Lisa Swanson, MD, PhD, reviews the indications for ruxolitinib, abrocitinib, and upadacitinib, as well as the clinical trial data on efficacy of these JAK inhibitors when treating AD.

Expert dermatologists discuss the factors that differentiate JAK inhibitors from other AD therapies, highlighting itch scores as they relate to quality of life.

These pivotal trial results from a study in China indicated the potential of this drug as a quarterly treatment for individuals with eczema.

Alexandra Golant, MD; Christopher Bunick, MD, PhD; and Peter Lio, MD, comment on how targeting the JAK-STAT (signal transducer and activator of transcription) pathway with JAK inhibitors plays a role in managing AD.

Peter Lio, MD, and Lisa Swanson, MD, PhD, provide an overview of Janus Kinase (JAK) inhibitors, their pathophysiology, and their mechanism of action in the treatment of atopic dermatitis (AD).